about
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Adherence to tuberculosis therapy among patients receiving home-based directly observed treatment: evidence from the United Republic of Tanzania.Epidemiology of tuberculosis in an urban slum of Dhaka City, BangladeshEffect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review.Health workers' performance in the implementation of Patient Centred Tuberculosis Treatment (PCT) strategy under programmatic conditions in Tanzania: a cross sectional studyPatient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study.Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.Implementation of a national anti-tuberculosis drug resistance survey in TanzaniaCare seeking in tuberculosis: results from a countrywide cluster randomised survey in BangladeshA randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.The effect of tuberculosis and antiretroviral treatment on CD4+ cell count response in HIV-positive tuberculosis patients in Mozambique.Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study.Socio economic position in TB prevalence and access to services: results from a population prevalence survey and a facility-based survey in Bangladesh.Adherence by Dutch public health nurses to the national guidelines for tuberculosis contact investigation.Are routine tuberculosis programme data suitable to report on antiretroviral therapy use of HIV-infected tuberculosis patients?Healthcare workers' challenges in the implementation of tuberculosis infection prevention and control measures in Mozambique.Comparison of direct versus concentrated smear microscopy in detection of pulmonary tuberculosis.Multidrug-resistant tuberculosis in Europe, 2010-2011Multidrug resistance among new tuberculosis cases: detecting local variation through lot quality-assurance samplingPredictive value of the tuberculin skin test among newly arriving immigrants.Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule.Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review.Evaluation of the Genotype® MTBDRplus assay as a tool for drug resistance surveys.Population impact of factors associated with prevalent pulmonary tuberculosis in Tanzania.Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial.Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy.Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients.Projection of the number of patients with tuberculosis in the Netherlands in 2030.Prevalence of smear-positive tuberculosis in persons aged ≥ 15 years in Bangladesh: results from a national survey, 2007-2009.Reply from the Authors of Limited Benefit of the New Shorter MDR-TB Regimen in Europe.Implementation of tuberculosis infection prevention and control in Mozambican health care facilities.Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.Prevalence of pulmonary tuberculosis in adult population of Tanzania: a national survey, 2012.Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.Risk assessment of tuberculosis in immunocompromised patients. A TBNET study.Health care-seeking behaviour among people with cough in Tanzania: findings from a tuberculosis prevalence survey.TB diagnostic process management of patients in a referral hospital in Mozambique in comparison with the 2007 WHO recommendations for the diagnosis of smear-negative pulmonary TB and extrapulmonary TB.Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.
P50
Q24802369-9B0AB363-B64B-4B63-9F2F-04FFF9238352Q28484444-74C388B1-43FA-4816-A0F3-20078293D06AQ28534563-5D597BD2-FC87-439F-B84A-A331EBBF48D4Q30240445-677D2CEE-EEF0-4A68-AC22-95CE9F24099DQ30394009-CD99F6C1-1340-48E8-9D53-47736386C65BQ30397124-0C5193D4-3AD8-45EB-BE29-06F21FFE67C9Q31150412-A20D0772-8494-455F-909A-7A462AFE9E95Q33396572-3E676B7E-1533-493F-A808-B30787B7418BQ33691418-691EE440-5DB5-47EC-8E1B-44401A083D46Q34191241-405EDC58-DEEB-4846-AEB3-750A66F70F6EQ34383081-8137880B-9270-4865-90C5-878B343A486EQ34385361-58E968A5-E605-4B90-AFF1-670AC52416B8Q34427810-45C3D1A8-5018-424A-993F-F8C2BDE82106Q34482655-F175B4C0-AF37-43DC-A4D8-C00AA6BDD802Q34554409-25E3A263-FF78-4AFA-9BF9-27CB04FBD229Q34703786-A74DD289-0B79-4738-9BBF-46B3C6134B12Q34865519-15DD090F-EB83-42EC-A152-EED574651618Q35130346-DFBA27C6-0CCF-4E22-900C-5D5D75A5AF0CQ35748536-304B6AB3-1D7D-4A7E-976A-07240666E8BDQ36721145-F082DC6C-E713-4D96-827F-1C60B09A03CAQ37108540-31A613EE-253E-45A5-AC93-57A791519154Q38216247-B356D10E-D4E1-4620-ADF2-D2621FDB9A61Q38422698-DD63BA83-6964-48C5-A4B5-B51E12C63EE7Q38812944-90AE6866-F4A5-48AA-A134-DE46D70C298CQ38851911-9048226A-FE50-4B23-BA3D-2BEEF75DD0B7Q38865952-9B99C5A7-4F07-40F8-82F7-BE9C848ABFD8Q38870064-77893003-4CEB-4872-B0EA-8D0EFF515DFAQ39038784-9A057D53-4C7E-484B-908E-DBC938CED61CQ39428882-FC1DFC65-51E3-413C-A3A6-C1BD64453205Q39988709-D5C75326-D5F8-4231-8A96-ACD2347BBDF5Q39996800-BE67988D-44CC-4C77-85B4-FEC913AB11D0Q40132080-F6628BB0-D31E-4D4E-8BDC-C7F796B92DF0Q40244418-334F5AAC-0492-4491-A4A6-87CB62D9E954Q40522723-2CA086DE-5433-4650-BBA3-04E10A3A6BCCQ40620275-C6CA2513-D9BB-4332-9176-217448461428Q40891947-07F8324E-E397-4392-B2E8-EDBAC9C8B8C0Q41706476-8BF94023-3367-47B2-BD75-71D01E02946EQ41758179-8DEF6AF0-DE92-477F-ABB7-47A011AB1DF3Q42244050-B492BCF6-7955-4E28-911D-93333B5B462CQ42715629-0633712D-E0B4-4D2B-8D55-D61995E8CDCB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Frank van Leth
@ast
Frank van Leth
@en
Frank van Leth
@es
Frank van Leth
@nl
type
label
Frank van Leth
@ast
Frank van Leth
@en
Frank van Leth
@es
Frank van Leth
@nl
prefLabel
Frank van Leth
@ast
Frank van Leth
@en
Frank van Leth
@es
Frank van Leth
@nl
P106
P1153
55906136900
6603474291
P21
P31
P496
0000-0002-5490-8968